Nedelcu Calin, Dijmarescu Irina, Patrascoiu Marina, Oprescu Ioana, Pacurar Daniela
Pediatrics, "Grigore Alexandrescu" Emergency Children's Hospital, Bucharest, ROU.
Pediatrics, "Carol Davila" University of Medicine and Pharmacy, Bucharest, ROU.
Cureus. 2024 Nov 8;16(11):e73299. doi: 10.7759/cureus.73299. eCollection 2024 Nov.
Lysosomal acid lipase deficiency (LAL-D) is an autosomal recessive genetic disease arising from mutations in the lipase A, lysosomal acid type (LIPA) gene, characterised by the formation of cholesterol esters and triglyceride storages, primarily in the liver and spleen. By analysing the level of lysosomal acid lipase (LAL), two forms were described in the literature: Wolman disease and cholesteryl-ester storage disease (CESD). Wolman disease usually manifests with rapidly progressive symptoms within the first year of life, while CESD is a latent condition, with significant features appearing later in life. LAL-D usually presents with a non-specific tableau, thus having the possibility of being incorrectly labelled. LAL activity can be demonstrated by LAL dried blood spot (DBS) testing. Since 2015, sebelipase alfa has been authorised for the treatment of LAL-D in the European Union, changing the course of this disease. This article aims to present two clinical cases of CESD and review the current literature on LAL-D. We presented two cases of CESD who were evaluated in our department for chronically elevated transaminases, one with and one without dyslipidaemia. For both patients, other causes of chronic hepatitis were excluded (viral infections, autoimmune diseases, and metabolic diseases), and LAL DBS testing was positive, establishing the diagnosis of CESD. One of them also underwent genetic testing, and a homozygous mutation of the LIPA gene was identified. LAL-D is a difficult diagnosis to establish, considering the scarcity of knowledge. In addition, neither the LAL DBS test nor LIPA gene sequencing investigations are largely available. Thus, most asymptomatic or minimally symptomatic patients might remain undiagnosed, and multiple complications without clear aetiology might arise, making this disease even harder to diagnose and manage. Nevertheless, even though the introduction of enzyme replacement therapy has improved outcomes for many patients, there still remains a need for increased awareness and understanding of this rare condition among health professionals.
溶酶体酸性脂肪酶缺乏症(LAL-D)是一种常染色体隐性遗传病,由溶酶体酸性脂肪酶A(LIPA)基因突变引起,其特征是胆固醇酯和甘油三酯蓄积,主要发生在肝脏和脾脏。通过分析溶酶体酸性脂肪酶(LAL)水平,文献中描述了两种形式:沃尔曼病和胆固醇酯贮积病(CESD)。沃尔曼病通常在生命的第一年内表现出快速进展的症状,而CESD是一种潜伏性疾病,显著特征在生命后期出现。LAL-D通常表现为非特异性症状,因此有可能被错误诊断。LAL活性可通过LAL干血斑(DBS)检测来证明。自2015年以来, sebelipase alfa已在欧盟被批准用于治疗LAL-D,改变了这种疾病的治疗进程。本文旨在介绍两例CESD临床病例,并回顾目前关于LAL-D的文献。我们介绍了两例因慢性转氨酶升高在我科接受评估的CESD病例,一例伴有血脂异常,一例不伴有血脂异常。对于这两名患者,均排除了慢性肝炎的其他病因(病毒感染、自身免疫性疾病和代谢性疾病),LAL DBS检测呈阳性,确诊为CESD。其中一名患者还进行了基因检测,发现了LIPA基因的纯合突变。考虑到相关知识的匮乏,LAL-D是一种难以确诊的疾病。此外,LAL DBS检测和LIPA基因测序检查都不太容易获得。因此,大多数无症状或症状轻微的患者可能仍未被诊断出来,可能会出现多种病因不明的并发症,使这种疾病更难诊断和管理。尽管如此,尽管酶替代疗法的引入改善了许多患者的治疗效果,但卫生专业人员仍需要提高对这种罕见疾病的认识和了解。